Apis Mellifera Aralia Racemosa Root Blatta Orienta

證據等級: L5 預測適應症: 0

目錄

  1. Apis Mellifera Aralia Racemosa Root Blatta Orienta
  2. Multi-Ingredient Homeopathic Combination: Evaluation Not Applicable — No Predictions Generated
    1. One-Sentence Summary
    2. Quick Overview
    3. Why No Prediction Was Generated
    4. US Market Information
    5. Safety Considerations
    6. Conclusion and Next Steps
    7. Disclaimer

## 藥師評估報告

Multi-Ingredient Homeopathic Combination: Evaluation Not Applicable — No Predictions Generated

One-Sentence Summary

This product is an 18-ingredient homeopathic/botanical combination formula whose constituents include bee venom (Apis mellifera), Galphimia glauca, Luffa operculata, Euphrasia, and other traditional allergy-associated botanicals — a composition pattern consistent with hay fever or upper respiratory allergy preparations.

The TxGNN model was unable to generate any repurposing predictions for this candidate, most likely because none of the 18 ingredients carry a valid DrugBank ID that can serve as a graph node in the knowledge graph.

There are no clinical trials and no literature records linked to this specific combination through the current pipeline.


Quick Overview

Item Content
Original Indication Not recorded
Predicted New Indication None generated
TxGNN Prediction Score N/A
Evidence Level N/A — Pipeline did not produce output
US Market Status Not marketed
Number of NDAs 0
Recommended Decision Hold

Why No Prediction Was Generated

The TxGNN repurposing pipeline requires at least one DrugBank-registered active ingredient as its graph entry point. For single-molecule drugs or well-characterised multi-component products (e.g., S-1, which maps to tegafur → DB09256), the knowledge graph can locate the drug node and propagate scores to disease nodes.

This product presents three structural barriers:

1. No single INN or DrugBank ID is available. The query was submitted as a semicolon-delimited string of 18 botanical and homeopathic source materials. The DrugBank query returned one result (result_count: 1), but no drugbank_id was stored in the Evidence Pack, suggesting the match was ambiguous or not a direct drug record.

2. Homeopathic source materials are not represented as pharmacological entities in the knowledge graph. Ingredients such as Blatta orientalis (cockroach), Lycoperdon utriforme (puffball mushroom), and Okoubaka aubrevillei bark exist in homeopathic materia medica but are absent from DrugBank’s pharmacological network. Without graph nodes, no disease-drug edges can be traversed.

3. MOA data is entirely absent. Without a mechanism of action, even a manual biological plausibility assessment cannot be performed.


US Market Information

No authorizations were found in Taiwan or the US FDA database for this combination. The regulatory query returned zero results.


Safety Considerations

No warnings, contraindications, or drug interaction data were found for this combination through the current pipeline. Please consult individual ingredient monographs in relevant pharmacopoeias (e.g., ESCOP, WHO Monographs on Selected Medicinal Plants) before any clinical consideration.


Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline cannot evaluate this product in its current form. The combination lacks a DrugBank-mappable active ingredient, has no INN, carries no regulatory approval in Taiwan or the US, and produced zero predicted indications. There is no computational or regulatory basis on which to proceed.

To unblock this candidate, the following is needed:

  • Identify the brand/product name: The ingredient profile (especially Galphimia glauca, Luffa operculata, Apis mellifera, Euphrasia) matches several commercial hay fever homeopathics (e.g., Pollinosan®, Luffa compositum®). Confirming the brand name would allow regulatory and literature searches to be re-run correctly.
  • Resolve the DrugBank match: The query log shows result_count: 1 from DrugBank but no drugbank_id was captured. The matched record should be inspected and the ID extracted if valid.
  • Reformulate as a per-ingredient analysis: If repurposing evaluation is still desired, each ingredient (e.g., Hydrastis canadensis / goldenseal, Silybum marianum / milk thistle, Solidago virgaurea / goldenrod) should be submitted as a separate, individual query so the knowledge graph can process each one independently.
  • Clarify regulatory scope: Homeopathic and combination botanical products are evaluated under different regulatory pathways (e.g., OTC homeopathic in the US, traditional herbal registration in EU). A TxGNN-style repurposing report may not be the appropriate output format for this product class.

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.



Copyright © 2026 UsTxGNN Project. For research purposes only.

This site uses Just the Docs, a documentation theme for Jekyll.